Doxorubicin

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

...lure and may occur as the total cumulative dose of doxorubicin HCl approaches 550 mg/m2 Prior use of o...lted in severe side effects. Do not substitute for doxorubicin HCl on a mg per mg basis Contraind...ry of hypersensitivity reactions to a conventional doxorubicin formulation or the components of DOXIL Nurs...

MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009

...ncer Susceptibility Gene (BRCA) deficiencies. Gynecological Cancers: Combination of carboplatin + pegylated liposomal doxorubicin will be the new standard-of-care for relapsed, platinum-sensitive ovarian cancer For advanced cervical cancer, the combination of gemcitabine ...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

...Florida, of results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer. Study Design : Patients with platinum refractory...

Study shows chemotherapy improves survival among older breast cancer patients

...pies provide better outcomes. For this trial, the standard chemotherapy consisted of either cyclophosphamide, methotrexate, and fluouracil (CMF) or doxorubicin plus cyclophosphamide. The single drug was the oral drug, capecitabine. Because patients often prefer oral to intravenous chemotherapy, a new effec...

Sunesis Reports Financial Results for the First Quarter 2009

...ty compared favorably with compounds currently in clinical use for the treatment of breast cancer, including cisplatin and topoisomerase II inhibitors doxorubicin and etoposide. Data also established an enhanced sensitivity to voreloxin in BRCA2 mutant cell lines, indicating that BRCA mutant tumors may be partic...

Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance

...alization of TELINTRA. In the fourth quarter, the top-line results from the ASSIST-5 trial of TELCYTA(R), in combination with pegylated liposomal doxorubicin (PDL) versus PDL alone, as second line therapy in platinum refractory, primary or secondary platinum resistant ovarian cancer were announced, and the ...

How chemotherapy drugs block blood vessel growth, slow cancer spread

... benefit from these drugs. The anthracycline class of chemotherapeutics doxorubicin (Adriamycin), daunorubicin, epirubicin, idarubicin have been used for four...rom human prostate cancer cells. They treated these mice with daunorubicin, doxorubicin or saline once a day for five days and measured tumor size. Tumors in salin...

Tiny Chemo Beads Boost Liver Cancer Outcomes

... first study, done at St. Joseph's Hospital and Medical Center in Tampa, Fla., 10 of 11 liver cancer patients given beads that released the chemo drug doxorubicin were alive two years after the procedure. Ten of the 13 people patients who had colorectal cancer that spread to the liver and were given the same tr...

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium

...cology's Breast Committee, presented "Phase II study of pegylated liposomal doxorubicin (PLD) and carboplatin (Cb) can be administered with trastuzumab (H) in pati...ones' study, "Docetexal plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US Oncology Trial 9...

Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update

...d Other Advanced Solid Tumors: Announced positive safety and efficacy data at ASCO from a Phase 1 clinical trial of picoplatin combined with liposomal doxorubicin in patients with advanced solid tumors, including ovarian cancer. Results demonstrated robust signals of clinical efficacy in ovarian cancer patients ...

Doxorubicin in Medical Technology

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that ...

Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting

Three-fold Lower Incidence of Severe Cardiac Toxicity With Equivalent Complete Remission Rates Reported ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that preliminary data from its phase II/III randomized stu...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCO Proceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) o...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trial anticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced the publication of preclinical studies, which demonstrate that treatment with pixantrone (BBR 2778) resulted in minimal o...

Alfacell Provides Shareholder Update

...DA exhibiting a significant survival advantage for those individuals previously treated with chemotherapy who received the combination of Onconase and doxorubicin points to molecular mechanisms of inherent or acquired chemotherapy resistance. It is known that there are specific chemotherapy resistance genes whic...

Telik Announces Presentation at ASCO Annual Meeting

...f canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American ...II study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refra...

Chemoembolization Improving as Liver Cancer Treatment

... were alive after two years. Conversely, one of 12 (8.3 percent) of the irinotecan patients were alive after two years. Researchers are studying why doxorubicin appears to work better in these cases. LC Beads slowly elute the chemotherapuetic agent over the course of two weeks, providing a constant dose o...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

...d may occur as the total cumulative dose of doxorubicin HCl approaches 550 mg/m2 - Prior use of o... severe side effects. Do not substitute for doxorubicin HCl on a mg per mg basis Contraindications ...ypersensitivity reactions to a conventional doxorubicin formulation or the components of DOXIL * Nurs...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

...ring cycles 1 through 4 and days 9 through 12 during only the first and second cycles. Patients in the VAD arm received vincristine at 0.4 mg/m(2) and doxorubicin at 9 mg/m(2) on days 1 through 4, and dexamethasone at 40 mg on days 1 through 4 during cycles 1 through 4 and on days 9 through 12 and 17 through 20 ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

...e believe that specifically targeting LHRH-receptor expressing tumors using doxorubicin is key to achieving increased clinical benefit for these patients. Finally,...antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin in women with LHRH-receptor positive gynaecological tumors", this European ...

Doxorubicin in Biological News

Nanodiamonds deliver insulin for wound healing

... also has studied nanodiamonds for applications in cancer therapy. They demonstrated that nanodiamonds are capable of releasing the chemotherapy agent doxorubicin in a sustained and consistent manner. (Ho is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.) In addition t...

Tumor growth and chemo response may be predicted by mathematical model

... pathology at The University of Texas M. D. Anderson Cancer Center, the researchers used the mathematical model to successfully predict the effects of doxorubicin on breast tumor growth. The model incorporates information gleaned from cancer cells grown in the laboratory to determine whether a prescribed drug wi...

Scientists can predict nano drug outcome

...substantially penetrated the tumor. When liposomal doxorubicin was administered, it was associated with better th...anometers. Nano drugs for cancer like liposomal doxorubicin are designed to increase the amount of drug reachi.... The current clinical protocols for liposomal doxorubicin consist of a standard dose every three to four wee...

Scattered light rapidly detects tumor response to chemotherapy

...eir experiments, the Duke team studied a well-known cell culture line of human breast cancer. The cells were exposed to two common chemotherapy drugs, doxorubicin and paclitaxel. Using the a/LCI technology, the researchers looked for specific patterns, which indicate that structural changes have occurred. The...

New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome

...take of the contrast agent by the tumors, as measured during the three-day imaging sessions, provided an accurate prognosis of the effect of liposomal doxorubicin on tumor growth rate. "When we plotted the post-treatment tumor growth rate versus the intensity of leakiness, there was a significant and strong c...

Nanodiamond drug device could transform cancer treatment

...he researchers demonstrated that the device releases the chemotherapy agent doxorubicin in a sustained and consistent manner -- a requirement of any implanted devi...ly released from the embedded nanodiamond clusters for one month, with more doxorubicin in reserve, indicating a more prolonged release (several months and longer)...

Promising new treatment option for women with recurrent ovarian cancer

... the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed o...erapy. Half the women received pegylated liposomal doxorubicin 30 mg/m2 over 60 min plus trabectedin 1.1mg/m2 ove... weeks, the remainder received pegylated liposomal doxorubicin 50 mg/m2 alone every 4 weeks. The median lengt...

Researchers develop nano-sized 'cargo ships' to target and destroy tumors

...y like a chocolate-covered nut cluster, in which a biocompatible lipid forms the chocolate shell and magnetic nanoparticles, quantum dots and the drug doxorubicin are the nuts. They sail through the bloodstream in groups that, under the electron microscope, look like small, broken strands of pearls. The resea...

New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients

... current standard treatments epirubicin and cyclophosphamide followed by a taxane, or TAC, another commonly used three-drug combination of docetaxel, doxorubicin and cyclophosphamide, said Professor von Minckwitz. ...

Launching a global alliance for pharmacogenomics

...romatase inhibitors) Determining the optimal length of treatment for two drugs used to treat early stage breast cancer (cyclophosphamide and either doxorubicin or paclitaxel) Discovering new genetic factors linked to serious side effects from certain pancreatic cancer drugs (gemcitabine and bevacizumab) ...

Doxorubicin in Biological Technology

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantr...

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer

PALO ALTO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced top-line results from an interrupted Phase 3 randomized study of Telcyta (canfosfamide HCL) in combination with pegylated liposomal doxorubicin (PLD) versus PLD alone in second-line therapy in pla...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

... Prognostic Index score (>=2). The median prior doxorubicin equivalent dose was approximately 300 mg/m2, the d... of three cycles in the comparator arm. The median doxorubicin equivalent dose at the end of therapy was 513 mg/m...ent dose related decline as has been described for doxorubicin with median LVEF values at a baseline of 58% and a...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...tion to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previo... study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone (Abstract 5550) ...the OVA-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD (Abstract...

Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

... # LBA515 Time: 3:00PM - 6:00PM Location: Level 2, West Hall D1 Breast cancer molecular profiles predict tumor response of neoadjuvant doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't Veer, J...

Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting

... on tumors in vivo. Combination index analyses revealed that TRU-016 is synergistic with rituximab, bendamustine, or rapamycin and additive with doxorubicin in killing NHL cells in vitro. In vivo results show that treatment with the combination of TRU-016 and bendamustine resulted in greater efficacy compa...

Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer

... pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing br...ated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesi...ast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy o...

Safer nanoparticles spotlight tumors, deliver drugs

...uld also help deliver drugs safely, the researchers report. The cancer drug doxorubicin will stick to the pores and slowly escape as the silicon dissolves. "Th...ug. At doses high enough to be effective, when delivered to the whole body, doxorubicin often has toxic side effects. At about 100 nanometers, these particles a...

Sopherion Therapeutics Secures $55 Million in Series C Funding

...unding to complete the pivotal Phase III clinical development program for its lead product candidate, Myocet(TM). Myocet is a liposomal formulation of doxorubicin designed to reduce the risk of cardiotoxicity while preserving antitumor efficacy. In January 2008, Zoticon Bioventures in-licensed Myocet and pr...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

... from a phase I/II study of nonpegylated liposomal doxorubicin (Myocet(R)) in the January 1 issue of Clinical Ca...ty. Myocet is a liposomal delivery system for doxorubicin designed to reduce the risk of cardiotoxicity associated with doxorubicin while preserving its antitumor efficacy. It is cu...